These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

224 related articles for article (PubMed ID: 33004416)

  • 21. A dose-dependent role for EBF1 in repressing non-B-cell-specific genes.
    Lukin K; Fields S; Guerrettaz L; Straign D; Rodriguez V; Zandi S; Månsson R; Cambier JC; Sigvardsson M; Hagman J
    Eur J Immunol; 2011 Jun; 41(6):1787-93. PubMed ID: 21469119
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Inhibition of inflammatory signaling in Pax5 mutant cells mitigates B-cell leukemogenesis.
    Isidro-Hernández M; Mayado A; Casado-García A; Martínez-Cano J; Palmi C; Fazio G; Orfao A; Ribera J; Ribera JM; Zamora L; Raboso-Gallego J; Blanco O; Alonso-López D; De Las Rivas J; Jiménez R; García Criado FJ; García Cenador MB; Ramírez-Orellana M; Cazzaniga G; Cobaleda C; Vicente-Dueñas C; Sánchez-García I
    Sci Rep; 2020 Nov; 10(1):19189. PubMed ID: 33154497
    [TBL] [Abstract][Full Text] [Related]  

  • 23. CD19 is a major B cell receptor-independent activator of MYC-driven B-lymphomagenesis.
    Chung EY; Psathas JN; Yu D; Li Y; Weiss MJ; Thomas-Tikhonenko A
    J Clin Invest; 2012 Jun; 122(6):2257-66. PubMed ID: 22546857
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Early B cell factor 1 regulates B cell gene networks by activation, repression, and transcription- independent poising of chromatin.
    Treiber T; Mandel EM; Pott S; Györy I; Firner S; Liu ET; Grosschedl R
    Immunity; 2010 May; 32(5):714-25. PubMed ID: 20451411
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Antagonism of B cell enhancer networks by STAT5 drives leukemia and poor patient survival.
    Katerndahl CDS; Heltemes-Harris LM; Willette MJL; Henzler CM; Frietze S; Yang R; Schjerven H; Silverstein KAT; Ramsey LB; Hubbard G; Wells AD; Kuiper RP; Scheijen B; van Leeuwen FN; Müschen M; Kornblau SM; Farrar MA
    Nat Immunol; 2017 Jun; 18(6):694-704. PubMed ID: 28369050
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Dynamic EBF1 occupancy directs sequential epigenetic and transcriptional events in B-cell programming.
    Li R; Cauchy P; Ramamoorthy S; Boller S; Chavez L; Grosschedl R
    Genes Dev; 2018 Jan; 32(2):96-111. PubMed ID: 29440261
    [TBL] [Abstract][Full Text] [Related]  

  • 27. The correlation between Pax5 deletion and patients survival in Iranian children with precursor B-cell acute lymphocytic leukemia.
    Moafi A; Zojaji A; Salehi R; Najafi Dorcheh S; Rahgozar S
    Cell Mol Biol (Noisy-le-grand); 2017 Aug; 63(8):19-22. PubMed ID: 28886309
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Oscillation between B-lymphoid and myeloid lineages in Myc-induced hematopoietic tumors following spontaneous silencing/reactivation of the EBF/Pax5 pathway.
    Yu D; Allman D; Goldschmidt MH; Atchison ML; Monroe JG; Thomas-Tikhonenko A
    Blood; 2003 Mar; 101(5):1950-5. PubMed ID: 12406913
    [TBL] [Abstract][Full Text] [Related]  

  • 29. PAX5 is a tumor suppressor in mouse mutagenesis models of acute lymphoblastic leukemia.
    Dang J; Wei L; de Ridder J; Su X; Rust AG; Roberts KG; Payne-Turner D; Cheng J; Ma J; Qu C; Wu G; Song G; Huether RG; Schulman B; Janke L; Zhang J; Downing JR; van der Weyden L; Adams DJ; Mullighan CG
    Blood; 2015 Jun; 125(23):3609-17. PubMed ID: 25855603
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Evaluation of PAX5 gene in the early stages of leukemic B cells in the childhood B cell acute lymphoblastic leukemia.
    Firtina S; Sayitoglu M; Hatirnaz O; Erbilgin Y; Oztunc C; Cinar S; Yildiz I; Celkan T; Anak S; Unuvar A; Devecioglu O; Timur C; Aydogan G; Akcay A; Atay D; Turkkan E; Karaman S; Orhaner B; Sarper N; Deniz G; Ozbek U
    Leuk Res; 2012 Jan; 36(1):87-92. PubMed ID: 21813177
    [TBL] [Abstract][Full Text] [Related]  

  • 31. STAT5 in B cell development and leukemia.
    Malin S; McManus S; Busslinger M
    Curr Opin Immunol; 2010 Apr; 22(2):168-76. PubMed ID: 20227268
    [TBL] [Abstract][Full Text] [Related]  

  • 32. LCK over-expression drives STAT5 oncogenic signaling in PAX5 translocated BCP-ALL patients.
    Cazzaniga V; Bugarin C; Bardini M; Giordan M; te Kronnie G; Basso G; Biondi A; Fazio G; Cazzaniga G
    Oncotarget; 2015 Jan; 6(3):1569-81. PubMed ID: 25595912
    [TBL] [Abstract][Full Text] [Related]  

  • 33. The role of the Janus-faced transcription factor PAX5-JAK2 in acute lymphoblastic leukemia.
    Schinnerl D; Fortschegger K; Kauer M; Marchante JR; Kofler R; Den Boer ML; Strehl S
    Blood; 2015 Feb; 125(8):1282-91. PubMed ID: 25515960
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Molecular role of the PAX5-ETV6 oncoprotein in promoting B-cell acute lymphoblastic leukemia.
    Smeenk L; Fischer M; Jurado S; Jaritz M; Azaryan A; Werner B; Roth M; Zuber J; Stanulla M; den Boer ML; Mullighan CG; Strehl S; Busslinger M
    EMBO J; 2017 Mar; 36(6):718-735. PubMed ID: 28219927
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Tungsten Blocks Murine B Lymphocyte Differentiation and Proliferation Through Downregulation of IL-7 Receptor/Pax5 Signaling.
    Wu TH; Bolt AM; Chou H; Plourde D; De Jay N; Guilbert C; Young YK; Kleinman CL; Mann KK
    Toxicol Sci; 2019 Jul; 170(1):45-56. PubMed ID: 30912803
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Aryl Hydrocarbon Receptor Activation Suppresses EBF1 and PAX5 and Impairs Human B Lymphopoiesis.
    Li J; Bhattacharya S; Zhou J; Phadnis-Moghe AS; Crawford RB; Kaminski NE
    J Immunol; 2017 Nov; 199(10):3504-3515. PubMed ID: 28978690
    [TBL] [Abstract][Full Text] [Related]  

  • 37. The reduced and altered activities of PAX5 are linked to the protein-protein interaction motif (coiled-coil domain) of the PAX5-PML fusion protein in t(9;15)-associated acute lymphocytic leukemia.
    Qiu JJ; Chu H; Lu X; Jiang X; Dong S
    Oncogene; 2011 Feb; 30(8):967-77. PubMed ID: 20972455
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Metabolic gatekeeper function of B-lymphoid transcription factors.
    Chan LN; Chen Z; Braas D; Lee JW; Xiao G; Geng H; Cosgun KN; Hurtz C; Shojaee S; Cazzaniga V; Schjerven H; Ernst T; Hochhaus A; Kornblau SM; Konopleva M; Pufall MA; Cazzaniga G; Liu GJ; Milne TA; Koeffler HP; Ross TS; Sánchez-García I; Borkhardt A; Yamamoto KR; Dickins RA; Graeber TG; Müschen M
    Nature; 2017 Feb; 542(7642):479-483. PubMed ID: 28192788
    [TBL] [Abstract][Full Text] [Related]  

  • 39. PAX5 promotes pre-B cell proliferation by regulating the expression of pre-B cell receptor and its downstream signaling.
    Xue K; Song J; Yang Y; Li Z; Wu C; Jin J; Li W
    Mol Immunol; 2016 May; 73():1-9. PubMed ID: 27016671
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Ebf1 and c-Myb repress rag transcription downstream of Stat5 during early B cell development.
    Timblin GA; Schlissel MS
    J Immunol; 2013 Nov; 191(9):4676-87. PubMed ID: 24068669
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.